ANTICARB
Monoclonal ANTIbody-targeted CARBon nanobues against cancer
| Coordinatore | UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Sito del progetto | http://anticarb.org/ |
| Totale costo | 3˙987˙793 € |
| EC contributo | 2˙967˙008 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-A |
| Funding Scheme | CP-FP |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-03-01 - 2011-08-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
UK (LONDON) | coordinator | 0.00 |
| 2 |
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Organization address
address: Rue Michel -Ange 3 contact info |
FR (PARIS) | participant | 0.00 |
| 3 |
HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
Organization address
address: Ingolstaedter Landstrasse 1 contact info |
DE (MUENCHEN) | participant | 0.00 |
| 4 |
NANOCYL SA
Organization address
address: RUE DE L'ESSOR 4 contact info |
BE (SAMBREVILLE) | participant | 0.00 |
| 5 |
SEROSCIENCE KUTATO FEJLESZTO ES KERESKEDELMI KORLATOLT FELELOSSEGU TARSASAG
Organization address
address: LORANT UTCA 10 B EP FSZT 2 contact info |
HU (BUDAPEST) | participant | 0.00 |
| 6 |
UCB PHARMA SA
Organization address
address: ALLEE DE LA RECHERCHE 60 contact info |
BE (BRUXELLES) | participant | 0.00 |
| 7 |
UNIVERSITA DEGLI STUDI DI TRIESTE
Organization address
address: PIAZZALE EUROPA 1 contact info |
IT (TRIESTE) | participant | 0.00 |
| 8 |
UNIVERSITY OF IOANNINA
Organization address
address: "LEOFOROS STAVROS S NIARCHOS, PANEPISTIMIOUPOLI IOANNINON" contact info |
EL (IOANNINA) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'ANTICARB attempts to exploit the advantages offered by a novel nanotechnology platform – carbon nanotubes – and apply them to a clinically established therapeutic modality – targeted antibody therapy – for the creation of hybrid nanotechnology-based monoclonal antibody targeted cancer therapeutics. ANTICARB combines two emerging technologies, antibody and nanotube technology, in a way that will allow safe development of antibody-nanotube conjugates and explore their swift translation into a clinical oncology setting. By combining proven, clinically used, anti-cancer agents – antibodies – with a novel nanotechnology-based platform made of advanced nanomaterials, ANTICARB aims at enhancing the therapeutic potency of the antibody and establish a new paradigm for oncology therapeutics. The ability of carbon nanotube technology to transport antibodies into the tumor cell cytoplasm may lead to validation of specific intracellular targets for oncology. This objective will be reached by adopting a multidisciplinary approach and by bringing together expertise from the fields of drug delivery, molecular biology, chemistry, engineering, pharmacology and toxicology. The proposal capitalises on this industry-academia multidisciplinary and perfectly integrated team, whose expertise spans from advanced biotech to sophisticated nanotechnology.'